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Introduction: Experimental evidence indicates vitamin D may play an important role in breast cancer etiology but
epidemiologic evidence to date is inconsistent. Vitamin D comes from dietary intake and sun exposure and plasma
levels of 25-hydroxyvitamin D (25(OH)D) are considered the best measure of vitamin D status.
Methods: We conducted a prospective nested case-control study within the Nurses’ Health Study II (NHSII). Plasma
samples collected in 1996 to 1999 were assayed for 25(OH)D in 613 cases, diagnosed after blood collection and
before 1 June 2007, and in 1,218 matched controls. Multivariate relative risks (RR) and 95% confidence intervals (CI)
were calculated by conditional logistic regression, adjusting for several breast cancer risk factors.
Results: No significant association was observed between plasma 25(OH)D levels and breast cancer risk (top vs.
bottom quartile multivariate RR = 1.20, 95% CI (0.88 to 1.63), P-value, test for trend = 0.32). Results were similar
when season-specific quartile cut points were used. Results did not change when restricted to women who were
premenopausal at blood collection or premenopausal at diagnosis. Results were similar between estrogen receptor
(ER)+/progesterone receptor (PR)+ and ER-/PR- tumors (P-value, test for heterogeneity = 0.51). The association did
not vary by age at blood collection or season of blood collection, but did vary when stratified by body mass index
(P-value, test for heterogeneity = 0.01).
Conclusions: Circulating 25(OH)D levels were not significantly associated with breast cancer risk in this
predominantly premenopausal population.
Introduction
Vitamin D is an essential component of the endocrine
system, responsible for calcium level maintenance, and
is hypothesized to be involved in many other body sys-
tems. There are two circulating forms of vitamin D: 25-
hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvita-
min D3 (1,25(OH)2D). 25(OH)D is the main form of cir-
culating vitamin D that is converted, by the 1a
hydroxylase enzyme, into 1,25(OH)2D, which is consid-
ered the biologically active metabolite, binding to
nuclear vitamin D receptors (VDR). However, although
1,25(OH)2D binds to VDR with 1,000 times the affinity
of 25(OH)D, the latter is more abundant suggesting its
interaction with VDR may not be trivial [1]. Although
the conversion of 25(OH)D primarily takes place in the
kidney, 1a hydroxylase also is present in breast and
other tissues, suggesting that some portion of 1,25(OH)
2D is produced and used locally [2-6]. 1,25(OH)2Di s
tightly regulated to maintain calcium homeostasis, while
25(OH)D serves as a pool for biologically active vitamin
D and thus is a marker of overall vitamin D status [7,8].
Experimental evidence supports an important role of
vitamin D in breast cancer etiology with 1,25(OH)2D
reducing proliferation and promoting differentiation and
apoptosis in breast cancer cell lines [9-11]. In animal
models, vitamin D inhibited growth of both estrogen
receptor (ER)+ and ER- tumors [12-14]. In a recent
study in breast cancer cells, 1,25(OH)2D decreased the
expression of aromatase [15]. Although aromatase in
adipose tissue plays an integral role in estrogen levels in
postmenopausal women, aromatase inhibitors may
increase ovarian estradiol production in premenopausal
women [16-19].
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(OH)D, comes from dietary and supplement intake as
well as sun exposure. Although several studies have
assessed sun exposure and dietary intake separately,
plasma levels of 25(OH)D are considered a better mar-
ker of vitamin D status because they incorporate all
sources of exposure as well as skin color, weight, and
other factors that influence an individual’s vitamin D
levels [20]. The association between circulating 25(OH)
D and breast cancer has been assessed in seven prospec-
tive studies with conflicting results [21-27]. Most studies
have included primarily or exclusively postmenopausal
women, with the exception of a small Finnish study (n
= 100 cases) in which plasma 25(OH)D levels measured
during pregnancy were not significantly associated with
subsequent breast cancer (RR = 1.4, 95% CI (0.6 to 3.4))
[25]. The inconsistent results overall and limited data in
premenopausal women, coupled with the potential pub-
lic health importance of vitamin D as a chemopreventive
agent, prompted our assessment of this association in
the prospective Nurses’ Health Study II (NHSII) cohort.
Materials and methods
Study population
The NHSII was established in 1989, when 116,430
female registered nurses, aged 25 to 42 years, completed
and returned a questionnaire. The cohort has been fol-
lowed biennially by questionnaire to update exposures
and ascertain newly diagnosed disease.
Between 1996 and 1999, 29,611 cohort members, who
were cancer-free and between the ages of 32 and 54
years, provided blood and urine samples. These women
were similar to the overall cohort with respect to life-
style factors, such as body mass index, parity, age at
menarche, past oral contraceptive use, and only differed
slightly in the prevalence of family history of breast can-
cer (19% vs. 15% in the overall cohort) [28]. Of the
29,611 women who gave blood, 18,521 were premeno-
pausal participants (that is, still having menstrual peri-
ods) who provided two blood samples and one urine
sample timed within the menstrual cycle (one follicular
sample collected on the third to fifth day and one luteal
sample collected seven to nine days before the antici-
pated start of their next cycle). Participants were sent a
short questionnaire and a blood and urine collection kit
containing the necessary supplies to have blood samples
drawn by a local laboratory or a colleague. Follicular
plasma was aliquotted by the participants 8 to 24 hours
after collection and stored in their home freezer until
the luteal collection. The day of the luteal collection, fol-
licular and luteal blood samples and luteal urine samples
were shipped, via overnight courier with an ice-pack, to
our laboratory where the luteal blood sample was pro-
cessed and separated into plasma, and red blood cell
and white blood cell components. Samples have been
stored in liquid nitrogen freezers (<-130°C) since collec-
tion. The study was approved by the Committee on the
Use of Human Subjects in Research at Harvard School
of Public Health and Brigham and Women’sH o s p i t a l .
Informed consent was implied by receipt of completed
questionnaires and blood samples.
Cases
Breast cancer cases were identified on biennial question-
naires; the National Death Index was searched for non-
responders. Cases had no previously reported cancer
diagnosis and were diagnosed with breast cancer after
blood collection but before 1 June 2007. Overall, 613
cases of breast cancer (n = 415 invasive) were reported
on biennial questionnaires and confirmed by medical
record review (n = 582) or verbal confirmation by the
nurse (n = 31). Given the 99% confirmation rate on
medical record review, these latter cases were included.
Information on invasiveness and hormone receptor sta-
tus was abstracted from the medical record. Mean time
from blood draw to diagnosis was 57 months (range = 1
to 127). Two controls were matched to each case (n =
1,218) on age (± 2 years); menopausal status at diagno-
sis; month/year of collection (± 2 months); ethnicity
(African-American, Asian, Hispanic, Caucasian, Other);
luteal day ((date of next period-date of luteal blood
draw) ± 1 day); and for each blood collection, time of
day (± 2 hours) and fasting status (< 2 hours, 2 to 4, 5
to 7, 8 to 11, 12+).
Laboratory assays
25(OH)D was assayed at Heartland Assays, Inc. (Ames,
IA, USA) using a radioimmunoassay with radioiodinated
tracers after acetonitrile extraction. Case-control sets
were assayed together and samples were ordered ran-
domly and labeled to mask case-control status. Samples
were assayed in two batches: cases (and matched con-
trols) diagnosed between 1999 and 2005 and those diag-
nosed from 2005 to 2007. The overall coefficients of
variation (CVs) from masked replicate quality control
samples included in each batch were 10.7% and 6.0%.
Due to technical difficulties with the assay, three case-
control sets failed and were removed, resulting in our
final study population of 613 cases and 1,218 controls.
Covariate data
We obtained breast cancer risk factor information from
a questionnaire completed at the time of blood collec-
tion and from the biennial NHSII questionnaires. Age at
menarche, weight at age 18, and height were queried in
1989. Age at first birth, parity, and diagnosis of benign
breast disease were assessed biennially. Family history of
breast cancer in the participant’s mother and sisters was
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time of blood collection.
Statistical analysis
Quartile cut points were defined in two ways, based on
the distribution in controls. The first set of cut points
was calculated among all controls. Next we calculated
season-specific cut points, using November to April
blood collection dates to define “winter” and May to
October blood collection dates to define “summer”.W e
identified statistical outliers using the generalized
extreme studentized deviate many-outlier detection
approach [29]. Although we identified seven participants
who had outlier values on the low end of the 25(OH)D
distribution (≤3.6 ng/ml (8.99 nmol/L)), we affirmed
that these were likely truly low levels given that most of
these blood samples were collected in winter months
and the participants had very low vitamin D dietary
intake (for example, 50 to 100 IU/day). Therefore, we
retained these values in the analysis.
We used conditional logistic regression to estimate
relative risks (RRs) and 95% confidence intervals (CIs)
to adjust for the matched design of this study. Multi-
variate models adjusted for body mass index (BMI) at
age 18 and at the time of blood collection, ages at
menarche and first birth, parity, family history of breast
cancer, and history of benign breast disease. Given that
outdoor physical activity may serve as a proxy for sun
exposure, an important source of vitamin D, our main
model did not include physical activity but we adjusted
for it in a sensitivity analysis. In stratified analyses, we
used unconditional logistic regression, adjusting for
matching factors, since results from multivariate uncon-
ditional and conditional logistic regression models were
essentially identical. To test whether the association dif-
f e r e db yE Ra n dP Rs t a t u so ft h et u m o r ,w eu s e dp o l y -
chotomous logistic regression [30] with three endpoints
(for example, ER+/PR+, ER-/PR-, and no breast cancer).
We used a likelihood ratio test to compare a model
with separate 25(OH)D slopes in each case group with
a model with a common slope. Wald tests for interac-
tion between stratification variables and hormones were
used to compare the slope of the quartile medians
between groups. Tests for trend were conducted by
modeling quartile median concentrations and calculat-
ing the Wald statistic. The shape of the dose-response
curves and tests for non-linearity were assessed using
restricted cubic spline models [31,32]. We used pre-
viously published reproducibility data [33] to correct for
random within-person and laboratory error [34]. All P-
values were based on two-sided tests and were consid-
ered statistically significant if ≤0.05. All analyses were
conducted using SAS software version 9 (SAS Institute,
Cary, NC, USA).
Results
Cases had slightly lower BMI at age 18 and at blood col-
lection and had gained less weight since age 18 than
controls (Table 1). Cases were more likely than controls
to be nulliparous and have a family history of breast
cancer and a history of benign breast disease.
In the simple conditional logistic regression model
accounting for matching factors only, women in the
h i g h e s tq u a r t i l eo f2 5 ( O H ) Dw e r en o ta ts i g n i f i c a n t l y
different risk of breast cancer compared with women in
the lowest quartile (RR = 1.26, 95% CI (0.94 to 1.69), P-
value, test for trend = 0.14) (Table 2). After adjustment
for breast cancer risk factors, the RR was slightly attenu-
ated (RR = 1.20, 95% CI (0.88 to 1.63), P-value, test for
trend = 0.32), with adjustment for BMI at blood collec-
tion accounting for the majority of the difference
between the simple and multivariate estimates. To assess
the impact of physical activity, which could be both a
confounder and a source of vitamin D, we added it to
our multivariate model; results still were not significant
(top vs. bottom quartile RR = 1.30, 95% CI (0.95 to
1.78), P-value, test for trend = 0.14). Analyses using sea-
son-specific cut points were similarly null (comparable
RR = 1.06, 95% CI (0.78 to 1.44), P-value, test for trend
= 0.79). Using restricted cubic spline models, no signifi-
cant linear or non-linear associations were detected.
Analyses by tumor subtype did not show any signifi-
cant differences (Table 2). When we restricted the ana-
lyses to invasive cases (N = 415), results were similar to
the overall (top vs. bottom RR = 1.29, 95% CI (0.92 to
1.81), P-value, test for trend = 0.14). RRs also were simi-
lar across hormone receptor subtypes (ER+ vs. ER- P-
value, test for heterogeneity = 0.41; ER+/PR+ vs. ER-/
PR- P-value, test for heterogeneity = 0.51).
To assess whether the association between 25(OH)D
levels and breast cancer risk differed by other factors,
we conducted secondary analyses restricted to premeno-
pausal women and women diagnosed more than two
years after blood collection. Results of analyses restricted
to women who were premenopausal at blood collection
(N = 470 cases) were still null (top vs. bottom quartile
RR = 1.23, 95% CI (0.87 to 1.73), P-value, test for trend
= 0.29), as were results of analyses restricted to women
premenopausal at diagnosis (N = 294 cases) (comparable
RR = 1.40, 95% CI (0.91 to 2.15), P-value, test for trend
= 0.16). Results also were unchanged when we excluded
cases diagnosed in the first two years (RR = 1.04, 95%
CI (0.74 to 1.47), P-value, test for trend = 0.91).
We also stratified by age at blood collection (< 45 vs.
≥ 45), BMI at blood collection (< 25 vs. ≥ 25 kg/m
2),
and season of blood collection (winter vs. summer)
(Table 3). When we stratified by BMI, we observed no
significant association among leaner women (top vs.
bottom quartile RR = 0.90, 95% CI (0.60 to 1.33), P-
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association among overweight and obese women (com-
parable RR = 1.90, 95% CI (1.19 to 3.03), P-value, test
for trend = 0.005). The interaction between plasma 25
(OH)D and BMI was statistically significant (P-value,
test for heterogeneity = 0.006) and a significant linear
association was observed in restricted cubic spline mod-
els for BMI ≥ 25 (P = 0.007) but no significant associa-
tion for BMI < 25 (P = 0.09). No non-linearity of 25
(OH)D in either BMI strata was evident. Results were
Table 1 Characteristics of breast cancer cases and matched controls, NHSII; mean ± SD or %
Cases (n = 613) Controls (n = 1,218)
Age at blood collection, y 45.0 ± 4.4 44.9 ± 4.4
Age at menarche, y 12.4 ± 1.3 12.4 ± 1.4
BMI at age 18, kg/m² 20.7 ± 2.9 21.1 ± 3.0
BMI at blood collection, kg/m² 25.5 ± 6.3 26.3 ± 7.1
Weight change since age 18, kg 11.6 ± 12.1 12.8 ± 13.8
Ever used oral contraceptives % 86 86
Duration of past oral contraceptives use, months* 47.4 ± 46.9 45.8 ± 45.6
Nulliparous, % 22 20
Parity, children
† 2.2 ± 0.9 2.3 ± 0.9
Age at first birth, y
† 26.6 ± 4.6 26.3 ± 4.6
Ever breast fed, %
† 78 80
Premenopausal at blood collection, % 77 76
Family history of breast cancer, % 17 10
History of benign breast disease, % 23 16
Plasma 25(OH)D level, ng/mL (nmol/L) 25.4 (63.4) ± 9.5 (23.7) 25.0 (62.4) ± 9.6 (24.0)
Time from blood collection to diagnosis, months 57.4 ± 33.5 NA
*Duration of oral contraceptive use among ever users
†Among parous women
Abbreviations: SD, standard deviation; BMI, body mass index; 25(OH)D, 25-hydroxyvitamin D; NA, not applicable
Table 2 Relative risks (95% CI) of breast cancer according to quartile of plasma 25(OH)D, NHSII
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-value, test for trend
Cut points (ng/mL)§ < 18.4 18.4 to < 24.6 24.6 to < 30.6 ≥ 30.6
Cases/controls 141/300 151/305 145/307 176/306
Simple 1.00 (ref) 1.06 (0.80 to 1.40) 1.02 (0.77 to 1.36) 1.26 (0.94 to 1.69) 0.14
Multivariate* 1.00 (ref) 1.05 (0.79 to 1.39) 0.95 (0.71 to 1.29) 1.20 (0.88 to 1.63) 0.32
Invasive Cases/controls 95/300 98/305 97/307 125/306
Multivariate* 1.00 (ref) 1.03 (0.74 to 1.44) 1.01 (0.72 to 1.42) 1.29 (0.92 to 1.81) 0.14
ER+
† Cases/controls 79/300 72/305 70/307 100/306
Multivariate* 1.00 (ref) 0.89 (0.62 to 1.29) 0.84 (0.57 to 1.23) 1.21 (0.84 to 1.75) 0.29
ER-
† Cases/controls 16/300 20/305 21/307 20/306
Multivariate* 1.00 (ref) 1.26 (0.63 to 2.54) 1.37 (0.67 to 2.79) 1.31 (0.63 to 2.74) 0.47
ER+/PR+
† Cases/controls 71/300 60/305 58/307 86/306
Multivariate* 1.00 (ref) 0.82 (0.56 to 1.22) 0.76 (0.51 to 1.15) 1.16 (0.79 to 1.71) 0.43
ER-/PR-
† Cases/controls 14/300 18/305 21/307 17/306
Multivariate* 1.00 (ref) 1.27 (0.61 to 2.65) 1.52 (0.73 to 3.19) 1.18 (0.54 to 2.60) 0.64
*Multivariate conditional logistic regression models adjusted for: age at menarche (< 12, 12, 13, ≥ 14 y), BMI at age 18 (< 21, 21 to < 23, ≥ 23 kg/m
2), parity and
age at first birth (nulliparous, one to two children and < 25 y, one to two children and 25 to 29 y, one to two children and ≥ 30 y, three or more children and <
25 y, three or more children and ≥ 25 y), BMI at blood collection (continuous), family history of breast cancer (yes/no), history of benign breast disease (yes/no).
Multivariate unconditional logistic regression models adjusted for above covariates and matching factors: age at blood collection (continuous), date of blood
collection (February to April, May to July, August to October, November to January), fasting status at blood collection (> 8 h/≤8 h), time of blood collection (1 to
4 am, 5 to 6 am, 7 am to 12 pm, continuous), luteal day (< 8, ≥ 8, untimed collection), race (Caucasian/other), menopausal status at blood collection
(premenopausal, postmenopausal, unknown menopausal status).
† P-value, test for heterogeneity from polytomous logistic regression: 0.41 for ER+ vs. ER-; 0.51 for ER+/PR+ vs. ER-/PR-
§Cut points in nmol/L are: < 45.9, 45.9 to < 61.4, 61.4 to < 76.4, ≥ 76.4
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; ref, referent; ER, estrogen receptor; PR, progesterone receptor
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value, test for heterogeneity = 0.29).
Additional stratified analyses included family history of
breast cancer and among blood samples collected from
premenopausal women in the luteal phase of the men-
strual cycle. Although there was a significant interaction
by family history of breast cancer (P-value, test for het-
erogeneity < 0.001), the numbers are small and the
effects in each strata of family history are not clear (for
example, quartiles 2, 3, 4 vs. quartile 1 RR = 1.15, 1.14,
1.19, P-value, test for trend = 0.33 for no family history
and RR = 0.54, 0.32, 1.49, P-value, test for trend = 0.31
for positive family history). Results among women with
luteal phase samples were similar to overall results (data
not shown).
The association between 25(OH)D and breast cancer
did not vary by season of blood collection using overall
cut points (top vs. bottom quartile summer RR = 1.17,
95% CI (0.74 to 1.88), P-value, test for trend = 0.39,
winter RR = 1.23, 95% CI (0.83 to 1.84), P-value, test for
trend = 0.44; P-value, test for heterogeneity = 0.33) or
season-specific cut points (top vs. bottom quartile sum-
mer RR = 0.97, 95% CI (0.63 to 1.52), P-value, test for
trend = 0.95, winter RR = 1.22, 95% CI (0.81 to 1.82), P-
value, test for trend = 0.52) (Table 3).
When we corrected for random within-person and
laboratory error using the reproducibility data (intraclass
correlation coefficient (ICC) = 0.72), results were largely
unchanged (for example, median of top vs. bottom quar-
tile RR = 1.09, 95% CI (0.86 to 1.36) uncorrected and
RR = 1.11, 95% CI (0.83 to 1.48) corrected).
Discussion
In this analysis among predominantly premenopausal
women, we did not observe an inverse association
between plasma 25(OH)D levels and breast cancer risk
overall. These results did not change when restricted to
invasive cases, cases diagnosed more than two years
after blood collection, or women who were premeno-
pausal at diagnosis. Results were not substantially differ-
ent between strata defined by age at blood collection or
season of blood collection. Stratification by BMI yielded
a significant interaction, with a significant positive asso-
ciation observed among overweight and obese women.
To date, only seven prospective studies of circulating
25(OH)D levels and breast cancer risk have been con-
ducted [21-27]. Results have been inconsistent, though
there have been few studies that have been able to
examine this association among premenopausal women.
In the NHS among mostly postmenopausal women,
increasing 25(OH)D was suggestively inversely asso-
ciated with breast cancer risk (top vs. bottom quintile
RR = 0.73, 95% CI (0.49 to 1.07), P-value, test for trend
= 0.06) [21]. Results from the Women’s Health Initiative
among postmenopausal women showed a non-signifi-
cant inverse association between plasma 25(OH)D levels
and breast cancer risk (top vs. bottom quintile RR =
0.82, P-value, test for trend = 0.20) [23]. However, other
recent reports among postmenopausal women from the
Prostate, Lung, Colorectal and Ovarian Cancer Screen-
ing Trial and the Cancer Prevention Study II (CPSII)
showed no associations (top vs. bottom quintile RR =
1.04 (P-value, test for trend = 0.81), 1.09 (P-value, test
Table 3 Stratified relative risks (95% CI) of breast cancer according to quartile of plasma 25(OH)D, NHSII
Quartile 1 Quartile 2 Quartile 3 Quartile 4 P-value, test for trend
Age at blood ≤45 Cases/controls 63/139 66/136 70/163 91/169
Multivariate* 1.00 (ref) 1.07 (0.69 to 1.67) 0.91 (0.58 to 1.41) 1.19 (0.77 to 1.84) 0.51
Age at blood > 45 Cases/controls 78/161 85/169 75/144 85/137
Multivariate* 1.00 (ref) 1.05 (0.71 to 1.55) 1.06 (0.70 to 1.61) 1.22 (0.80 to 1.85) 0.35
BMI < 25 Cases/controls 77/121 88/149 84/192 109/216
Multivariate* 1.00 (ref) 0.99 (0.66 to 1.48) 0.75 (0.50 to 1.13) 0.90 (0.60 to 1.33) 0.45
BMI ≥ 25 Cases/controls 64/179 63/156 61/115 67/90
Multivariate* 1.00 (ref) 1.09 (0.71 to 1.67) 1.45 (0.92 to 2.28) 1.90 (1.19 to 3.03) 0.005
Summer Cut points < 21.2 21.2 to < 27.1 27.1 to < 32.7 ≥ 32.7
Cases/controls 73/142 70/142 73/143 71/144
Multivariate* 1.00 (ref) 0.95 (0.62 to 1.45) 0.99 (0.65 to 1.53) 0.97 (0.63 to 1.52) 0.95
Winter Cut points < 16.5 16.5 to < 22.7 22.7 to < 28.4 ≥ 28.4
Cases/controls 71/161 83/159 78/165 94/162
Multivariate* 1.00 (ref) 1.22 (0.82 to 1.83) 0.98 (0.65 to 1.47) 1.22 (0.81 to 1.82) 0.52
*Multivariate unconditional logistic regression models adjusted for covariates and matching factors listed in Table 2.
P-value, test for heterogeneity: age at blood collection P = 0.29; BMI at blood collection P = 0.01; season of blood collection P = 0.52.
§Cut points in nmol/L are: Summer < 52.9, 52.9 to < 67.6, 67.6 to < 81.6, ≥ 81.6; Winter < 41.2, 41.2 to < 56.7, 56.7 to < 70.9, ≥ 70.9
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; ref, referent
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Mälmo Diet and Cancer Study, no association with total
25(OH)D was observed overall (top vs. bottom quartile
RR = 0.96, P-value, test for trend = 0.78) and a non-sig-
nificant positive association was observed among the 196
premenopausal cases (top vs. bottom quartile RR = 1.74,
95% CI (0.84 to 3.60), P-value, test for trend = 0.14) [26].
In contrast, the suggested inverse association with serum
25(OH)D in the E3N cohort was stronger among the
small numbers of premenopausal women (N = 54) (top
vs. bottom tertile OR = 0.37, 95% CI (0.12 to 1.15), P-
trend = 0.11) [27]. In a small Finnish study of premeno-
pausal women (n = 100 cases), plasma 25(OH)D levels
measured during pregnancy were not significantly asso-
ciated with breast cancer risk (top vs. bottom quartile RR
= 1.4, 95% CI (0.6 to 3.4), P-value, test for trend = 0.4)
[25]. Our current study, the largest to date among pre-
menopausal women, shows no significant association
between plasma 25(OH)D levels and breast cancer risk.
The significant interaction we observed by BMI was
unexpected. Although a significant interaction by BMI
also was observed in the NHS study of 25(OH)D and
colon cancer, in that study, a stronger inverse associa-
tion was observed among leaner women [35]. Five prior
studies of the association between 25(OH)D levels and
breast cancer risk, again among primarily postmenopau-
sal women, reported no significant difference by BMI
[21,22,24,26,27]. Upon further exploration, we noted
that those with higher 25(OH)D levels in the BMI ≥ 25
group had higher levels of physical activity than those
with lower 25(OH)D levels. Although one hypothesis is
that this could reflect fewer anovulatory cycles in over-
weight and obese women with high vitamin D, physical
activity was inversely associated with breast cancer risk
in premenopausal women in this cohort and there was
not a significant difference in this association by BMI
[36]. Adjusting for confounding by physical activity in
the analysis yielded slightly stronger RRs. Another
hypothesis is that overweight women with higher 25
(OH)D levels do not benefit from the reduced risk of
breast cancer associated with higher BMI in premeno-
pausal women. This is possible given that 25(OH)D
levels may inhibit aromatase, which in turn could lead
to increased ovarian estrogen production in premeno-
pausal women [15-19]. It also is possible that this find-
ing of a significant interaction is due to chance; this
warrants further exploration in other studies.
The prior analysis in the NHS suggested that higher
25(OH)D levels may be associated with a lower risk of
ER- or ER-/PR- disease, but no difference by hormone
receptor status was observed in the CPSII cohort
[21,24]. In this study of predominantly premenopausal
women, we did not observe significant differences by
hormone receptor status.
This study has several strengths, including the large
number of premenopausal cases, extensive information
on potential confounders, and blood samples collected
before diagnosis. Although this analysis includes only
one measure of plasma 25(OH)D to represent longer-
term exposure, we have showed good reproducibility of
this analyte over a two- to three-year period in the NHS
(ICC = 0.72) [33].
Conclusions
While higher plasma 25(OH)D levels have been
hypothesized to reduce breast cancer risk, our results
suggest such a benefit may not be observed among pre-
menopausal women.
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